SCHEMBL5508965

SCHEMBL5508965

CCOc1cc2c(cc1OC)C(c1cccc(-c3nnn(CC)n3)c1)=N[C@@H]1CC[C@@H](O)C[C@H]21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 3/20 0.38
TP53 P04637 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 5/20 0.37
USP2 O75604 3/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
TRPM8 Q7Z2W7 2/20 0.35
HPGD P15428 1/20 0.34
TRPV1 Q8NER1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5507093 1.00 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL5623021 0.94 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL5621856 0.86 PDE4D (0.45) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL5623979 0.86 PDE4D (0.45) PDE4APDE4BPDE4CPDE4DMEN1
Hydrochloric Acid SCHEMBL7211921 0.85 PDE4D (0.60) PDE4APDE4BPDE4CPDE4DMEN1
Hydrochloric Acid SCHEMBL7206863 0.85 PDE4D (0.60) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL6387528 0.85 PDE4D (0.47) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL5478908 0.84 PDE4D (0.46) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL5507773 0.84 PDE4D (0.42) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL5502702 0.84 PDE4D (0.42) PDE4APDE4BPDE4CPDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors ATLANTA PHARMA AG (DE) 2007-08-16 US claimed
EP-1812400-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2007-08-01 EP claimed
WO-2005090311-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO claimed
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors ATLANTA PHARMA AG (DE) 2007-08-16 US disclosed
EP-1812400-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2007-08-01 EP disclosed
WO-2005090311-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors PDE4A, PDE4B, PDE4C PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.